Cancer Genetics Reports Second Quarter 2019 Financial Results and Provides Strategic Business Update
August 20, 2019 08:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic,...
Cancer Genetics, Inc. Announces Strategic Transactions
July 15, 2019 16:22 ET
|
Cancer Genetics, Inc.
Sale of BioPharma business to Interpace Diagnostics Group, Inc. Clinical services business acquired by siParadigm Diagnostic Informatics Significantly reduces its debt burden and will continue to...
Cancer Genetics Reports First Quarter 2019 Financial Results and Provides Strategic Business Update
May 20, 2019 17:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., May 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics,...
Cancer Genetics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Strategic Business Updates
April 16, 2019 07:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., April 16, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics,...
Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock
January 31, 2019 16:01 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers...
Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock
January 28, 2019 22:33 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers...
Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock
January 28, 2019 16:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers...
Cancer Genetics Issues Letter to Shareholders
January 16, 2019 08:45 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers...
Cancer Genetics, Inc. Announces Closing of Public Offering of Common Stock
January 14, 2019 17:29 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers...
Cancer Genetics, Inc. Announces Pricing of Public Offering of Common Stock
January 09, 2019 23:20 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Jan. 09, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers...